|Bid||8.10 x 900|
|Ask||8.15 x 1200|
|Day's range||7.69 - 8.34|
|52-week range||7.37 - 94.17|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||26.09|
|Earnings date||11 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.67|
BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of
Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.
Shares of Atea Pharmaceuticals (NASDAQ: AVIR) fell by as much as 14.4% in premarket trading Wednesday morning. The biotech's shares are sliding today in response to Roche's (OTC: RHHBY) decision to terminate its involvement in the development of the oral COVID-19 therapy known as AT-527. Atea Pharmaceuticals will reportedly regain full commercial rights to the drug on Feb. 10, 2022.